TickerFacts.

NextCure, Inc. (NXTC): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$55.42M
Year ended 2025-12-31
2018-12-31: -$21.52M2019-12-31: -$34.79M2020-12-31: -$37.83M2021-12-31: -$66.47M2022-12-31: -$71.81M2023-12-31: -$63.94M2024-12-31: -$56.85M2025-12-31: -$55.42M-$55.42M
2018-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$55.42Mn/m2026-03-05, From 2025-01-01
2024-12-31-$56.85Mn/m2026-03-05, From 2024-01-01
2023-12-31-$63.94Mn/m2025-03-06, From 2023-01-01
2022-12-31-$71.81Mn/m2024-03-21, From 2022-01-01
2021-12-31-$66.47Mn/m2023-03-02, From 2021-01-01
2020-12-31-$37.83Mn/m2022-03-03, From 2020-01-01
2019-12-31-$34.79Mn/m2021-03-04, From 2019-01-01
2018-12-31-$21.52Mn/a2020-03-12, From 2018-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
NextCure, Inc. (NXTC)2025-12-31-$55.42Mn/m
Hyperion Defi, Inc. (HYPD)2024-12-31-$47.61Mn/m
Actinium Pharmaceuticals, Inc. (ATNM)2025-12-31-$36.07Mn/m
Vistagen Therapeutics, Inc. (VTGN)2026-03-31-$71.93Mn/m
Akari Therapeutics Plc (AKTX)2024-12-31-$21.63Mn/m
Spruce Biosciences, Inc. (SPRB)2025-12-31-$36.49Mn/m
Medicinova Inc (MNOV)2025-12-31-$13.26Mn/m
Connect Biopharma Holdings Ltd (CNTB)2025-12-31-$57.37Mn/m
Bolt Biotherapeutics, Inc. (BOLT)2025-12-31-$34.82Mn/m

Compare NXTC, HYPD, ATNM, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗